PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27029378-2	2016	In the present study, we developed self-cross-linked biodegradable poly(ethylene glycol)-b-poly(l-lysine)-b-poly(l-cysteine) (LCss) polypeptide nanoparticles to codeliver DOX and miR-129-5p, which aimed to overcome MDR in cancer cells.	poly(ethylene glycol)-b-poly(l-lysine)-b-poly(l-cysteine)	67-124	microRNA 1295a	Homo sapiens	179-189	
27029378-4	2016	The codelivery of miR-129-5p and DOX with LCss (DLCss/miR) significantly increased miR-129-5p expression over 100-fold in MCF-7/ADR cells, which effectively overcame MDR by directly inhibiting P-glycoprotein (P-gp), thereby increasing intracellular DOX accumulation and cytotoxicity in MCF-7/ADR cells.	Doxorubicin	33-36	ATP binding cassette subfamily B member 1	Homo sapiens	193-207	
27029378-4	2016	The codelivery of miR-129-5p and DOX with LCss (DLCss/miR) significantly increased miR-129-5p expression over 100-fold in MCF-7/ADR cells, which effectively overcame MDR by directly inhibiting P-glycoprotein (P-gp), thereby increasing intracellular DOX accumulation and cytotoxicity in MCF-7/ADR cells.	Doxorubicin	33-36	ATP binding cassette subfamily B member 1	Homo sapiens	209-213	
27029378-4	2016	The codelivery of miR-129-5p and DOX with LCss (DLCss/miR) significantly increased miR-129-5p expression over 100-fold in MCF-7/ADR cells, which effectively overcame MDR by directly inhibiting P-glycoprotein (P-gp), thereby increasing intracellular DOX accumulation and cytotoxicity in MCF-7/ADR cells.	Doxorubicin	249-252	microRNA 1295a	Homo sapiens	18-28	
27029378-4	2016	The codelivery of miR-129-5p and DOX with LCss (DLCss/miR) significantly increased miR-129-5p expression over 100-fold in MCF-7/ADR cells, which effectively overcame MDR by directly inhibiting P-glycoprotein (P-gp), thereby increasing intracellular DOX accumulation and cytotoxicity in MCF-7/ADR cells.	Doxorubicin	249-252	MLX interacting protein	Homo sapiens	18-21	
27029378-4	2016	The codelivery of miR-129-5p and DOX with LCss (DLCss/miR) significantly increased miR-129-5p expression over 100-fold in MCF-7/ADR cells, which effectively overcame MDR by directly inhibiting P-glycoprotein (P-gp), thereby increasing intracellular DOX accumulation and cytotoxicity in MCF-7/ADR cells.	Doxorubicin	249-252	microRNA 1295a	Homo sapiens	18-27	
27029378-4	2016	The codelivery of miR-129-5p and DOX with LCss (DLCss/miR) significantly increased miR-129-5p expression over 100-fold in MCF-7/ADR cells, which effectively overcame MDR by directly inhibiting P-glycoprotein (P-gp), thereby increasing intracellular DOX accumulation and cytotoxicity in MCF-7/ADR cells.	Doxorubicin	249-252	ATP binding cassette subfamily B member 1	Homo sapiens	193-207	
27029378-4	2016	The codelivery of miR-129-5p and DOX with LCss (DLCss/miR) significantly increased miR-129-5p expression over 100-fold in MCF-7/ADR cells, which effectively overcame MDR by directly inhibiting P-glycoprotein (P-gp), thereby increasing intracellular DOX accumulation and cytotoxicity in MCF-7/ADR cells.	Doxorubicin	249-252	ATP binding cassette subfamily B member 1	Homo sapiens	209-213	
27029378-5	2016	Furthermore, miR-129-5p also partially diminished cyclin-dependent kinase 6 (CDK6), and synergized with DOX to simultaneously decrease S phase and induce G2 phase cell cycle arrest, thereby further enhancing the chemosensitivity of MCF-7/ADR cells.	Doxorubicin	104-107	microRNA 1295a	Homo sapiens	13-23